ANI Pharmaceuticals

ANI PHARMACEUTICALS INC

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Oakville,,On,,Canada,-,August,15,,2021:,Close,Up,Of

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

ANIP

ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by Cortrophin Gel and brand expansion.

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

Portland,,Oregon,-may,11,2019:,Southwest,Airlines,Passenger,Planes,At

Pre-Market Outlook

Markets

CFFI

NAMS

RLGT

SIBN

SLXN

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

AEON

BBAI

BLRX

DOYU

GCTK

LUXH

PMAX

QUBT

RIME

SANG

SOBR

SONM

TNXP

WHLR

Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

ANI Pharmaceuticals Inc

Press Releases

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

Alcami Announces CEO Transition

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

Contracts

ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

BGM Group

Belite Bio, Inc - American Depositary Shares

Belite Bio

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Harrow

Indivior

Innoviva

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Ocular Therapeutix

Organon

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pacira BioSciences

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Verona Pharma plc - American Depositary Shares

Verona Pharma

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

HC Wainwright & Co.

Jefferies

JP Morgan

Guggenheim

Leerink Partners

Comments

ANI Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga